KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBT Margin (2016 - 2026)

West Pharmaceutical Services has reported EBT Margin over the past 18 years, most recently at 21.32% for Q1 2026.

  • Quarterly EBT Margin rose 549.0% to 21.32% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 20.82% through Mar 2026, up 118.0% year-over-year, with the annual reading at 19.55% for FY2025, 69.0% down from the prior year.
  • EBT Margin was 21.32% for Q1 2026 at West Pharmaceutical Services, up from 20.06% in the prior quarter.
  • Over five years, EBT Margin peaked at 29.46% in Q2 2022 and troughed at 15.83% in Q1 2025.
  • The 5-year median for EBT Margin is 21.36% (2025), against an average of 21.64%.
  • Biggest five-year swings in EBT Margin: tumbled -673bps in 2022 and later surged 549bps in 2026.
  • Tracing WST's EBT Margin over 5 years: stood at 18.16% in 2022, then grew by 27bps to 22.98% in 2023, then decreased by -4bps to 22.02% in 2024, then decreased by -9bps to 20.06% in 2025, then increased by 6bps to 21.32% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 21.32%, 20.06%, and 21.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.